Evidence map›Paper›PMID 40853122›Full record

ArticlemBio2025

CCL20/CCR6 signaling modulates disease severity during the establishment of

Himanshu Meghwani, Javier Rangel-Moreno, Kyra M Sandercock, Motoo Saito, Katya A McDonald, Chloe M Kraft, Robert Constantine, Sophia Lenigk, Adryiana Rodriguez, Stephen L Kates and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Himanshu MeghwaniDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0003-4190-2046
Javier Rangel-MorenoDivision of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
Kyra M SandercockDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Motoo SaitoDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Katya A McDonaldDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0001-8919-3651
Chloe M KraftDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0009-0001-9591-6841
Robert ConstantineDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Sophia LenigkDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Adryiana RodriguezDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Stephen L KatesDepartment of Orthopedics, Virginia Commonwealth University, Richmond, Virginia, USA.
Jennifer H JonasonDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Edward M SchwarzDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Gowrishankar MuthukrishnanDepartment of Orthopedics, Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.ORCID 0000-0001-7521-6154

Funding

ROLE OF INDUCIBLE BRONCHUS ASSOCIATED LYMPHOID TISSUE IN LATENT TUBERCULOSISR01AI111914 · NIAID · WASHINGTON UNIVERSITY · PI KAUSHAL, DEEPAK, KHADER, SHABAANA A. · 2015 to 2025
$11.1M
Rochester Resource-Based Center for Bone, Muscle and Orthopaedic Research (ROCSTARR) (Overall Application)P30AR069655 · NIAMS · UNIVERSITY OF ROCHESTER · PI Edward M. Schwarz · 2016 to 2026
$7.8M
Training in Musculoskeletal Science: Comprehensive Training in Pain StudiesT32AR076950 · NIAMS · UNIVERSITY OF ROCHESTER · PI Hani A Awad, Laura M Calvi · 2020 to 2026
$1.7M
American Association of Immunologists Careers in ImmunologyNIAID NIH HHS R01 AI111914NIAMS NIH HHS P30 AR069655NIAMS NIH HHS P50 AR07200NIAMS NIH HHS T32 AR076950
6 · The paper itself

Abstract

Chemokines are essential mediators of immune responses, and the CCL20/CCR6 chemokine signaling axis is known to be involved in inflammation, infectious diseases, and cancer progression. However, the role of the CCL20/CCR6 axis in host defense against IMPORTANCE:

Indexed as

Chemokine CCL20OsteomyelitisReceptors, CCR6Signal TransductionStaphylococcal InfectionsStaphylococcus aureusAnimalsDisease Models, AnimalFemaleHumansMacrophagesMaleMiceMice, Inbred C57BLMice, KnockoutOsteoblastsCCL20 protein, humanCCL20 protein, mouseCCR6 protein, humanCCR6 protein, mouseChemokine CCL20Receptors, CCR6CCL20CCR6host immunityosteomyelitisStaphylococcus aureusT cells

Identifiers

PMID40853122
PMCPMC12506002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.